Project Details
Description
A phase I study to evaluate the effect of NKTR-102 for injection (etirinotecan pegol) on the QT/QTc interval in patients with advanced or metastatic solid tumors
| Status | Finished |
|---|---|
| Effective start/end date | 4/15/14 → 4/18/19 |
Funding
- NEKTAR THERAPEUTICS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.